Findings during the COVID-19 pandemic indicating how angiotensin II type 1 receptor antagonists (ARAs) might also indirectly promote ACE2 expression, suggest that ARAs might similarly have a benefit in Alzheimer's disease by reducing classic RAS (involved in angiotensin II signalling) activity, while promoting regulatory RAS (involved in angiotensin II metabolism).8 The gene discussed is AGT; the disease is early-onset autosomal dominant Alzheimer disease.